Abstract
Risedronate is a nitrogen-containing bisphosphonate for the treatment and prevention of post-menopausal osteoporosis. The current work aims to develop a novel green HPLC-UV method for the rapid analysis of risedronate sodium in bulk and tablet formulation. The analyzed samples were separated on Waters Atlantis dC18 (150 mm x 3.9 mm; 5 mu m) column using a green mobile phase consisting of potassium phosphate buffer pH 2.9 and potassium edetate buffer pH 9.5 in a ratio of 1:2, the final pH was adjusted to 6.8 with phosphoric acid, the mobile phase was pumped at a rate of 1.0 mL/min, with column temperature set at 30 degrees C, eluted samples were detected at 263 nm and the chromatographic run time was 3.0 min. The method was found to be linear over the concentration range of 14-140 mu g/mL with a correlation coefficient (r(2)) of 0.9994. Accuracy and precision were evaluated from three QC samples (LQC, MQC and HQC) together with the five calibrators where the percentage accuracy was found to be 101.84%. Processed quality control samples of risedronate sodium were tested for stability at different conditions, short term, long term and freezethaw stability. The current method was further extended to study the content uniformity of Actonel (R) tablets following United States Pharmacopoeia (USP) guidelines. The proposed method was fully validated as per ICH guidelines. (C) 2020 The Author(s). Published by Elsevier B.V.